Full Press Release Details
Awarded Its Third Non-Dilutive Israel Innovation Authority Grant
Support the Clinical Development of Allocetra in Sepsis Patients
Nes Ziona, Israel, May 25, 2022 (GLOBE NEWSWIRE) -- Enlivex
Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients
with sepsis and solid tumors, today announced that the Israel Innovation Authority (IIA) selected Enlivex's ongoing sepsis clinical
program to receive a thirdnon-dilutive grant of approximately $1.2 million for 2022. To date, Enlivex has received a total of approximately
$7.8 million in non-dilutive grants from the IIA for clinical trials and product development, excluding this newly approved grant.
The IIA is an independent, publicly funded agency charged with fostering
the development of industrial research and development within the State of Israel. It provides non-dilutive grants in the form of reimbursement
for actual expenses pre-approved by the IIA. The grants become repayable only through royalties from future sales of products developed
with the support of the IIA, and the repayment, if any, is limited to the original grant amount plus interest.
Enlivex is currently recruiting patients to its Phase IIb trial of
AllocetraTM for the treatment of organ dysfunction associated with sepsis.
Enlivex is developing AllocetraTM
as a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid
cancers, sepsis, and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly
to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide a
novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as "unmet medical needs",
as a stand-alone therapy or in combination with leading therapeutic agents.
Enlivex is a clinical stage macrophage reprogramming immunotherapy company developing Allocetra , a universal, off-the-shelf cell
therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic
state is critical for immune system rebalancing and resolution of life-threatening conditions. For more information visit https://enlivex.com/.
Safe Harbor Statement: This press
release contains forward-looking statements, which may be identified by words such as "expects," "plans," "projects,"
"will," "may," "anticipates," "believes," "should," "would", "could,"
"intends," "estimates," "suggests," "has the potential to" and other words of similar
meaning, including statements regarding expected cash balances, market opportunities for the results of current clinical studies and preclinical
experiments, the effectiveness of, and market opportunities for, ALLOCETRATM programs. All such forward-looking statements
are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned
that forward-looking statements involve risks and uncertainties that may affect Enlivex's business and prospects, including the
risks that Enlivex may not succeed in generating any revenues or developing any commercial products; that the products in development
may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing
of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial
or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking
statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other
trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials.
The development of any products using the ALLOCETRATM product line could also be affected by a number of other factors,
including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the
impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary
rights held by competitors and other third parties. In addition to the risk factors described above, investors should consider the
economic, competitive, governmental, technological and other factors discussed in Enlivex's filings with the Securities and Exchange
Commission, including in the Company's most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission.
The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake
any obligation to update forward-looking statements, except as required under applicable law.
Shachar Shlosberger, CFO
Enlivex Therapeutics, Ltd.